FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Good-bye, Old Friend January 8, 2021 Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type... August 5, 2024 ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ December 16, 2018 Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Load more HOT NEWS 5 Tips to Move Beyond the Bedside Can Eating Soy Cause Breast Cancer? No Improvement in OS with Adding Palbociclib to Letrozole for the... How Being an Athlete Prepared Me for My Cancer Experience
